Purity for clarity: the need for purification of tumor cells in DNA microarray studies
- PMID: 15744349
- DOI: 10.1038/sj.leu.2403685
Purity for clarity: the need for purification of tumor cells in DNA microarray studies
Abstract
It is now well established that gene expression profiling using DNA microarrays can provide novel information about various types of hematological malignancies, which may lead to identification of novel diagnostic markers. However, to successfully use microarrays for this purpose, the quality and reproducibility of the procedure need to be guaranteed. The quality of microarray analyses may be severely reduced, if variable frequencies of nontarget cells are present in the starting material. To systematically investigate the influence of different types of impurity, we determined gene expression profiles of leukemic samples containing different percentages of nonleukemic leukocytes. Furthermore, we used computer simulations to study the effect of different kinds of impurity as an alternative to conducting hundreds of microarray experiments on samples with various levels of purity. As expected, the percentage of erroneously identified genes rose with the increase of contaminating nontarget cells in the samples. The simulations demonstrated that a tumor load of less than 75% can lead to up to 25% erroneously identified genes. A tumor load of at least 90% leads to identification of at most 5% false-positive genes. We therefore propose that in order to draw well-founded conclusions, the percentage of target cells in microarray experiment samples should be at least 90%.
Similar articles
-
Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks.Leukemia. 2006 Aug;20(8):1385-92. doi: 10.1038/sj.leu.2404274. Epub 2006 Jun 8. Leukemia. 2006. PMID: 16761018
-
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.Leukemia. 2005 Jun;19(6):1042-50. doi: 10.1038/sj.leu.2403749. Leukemia. 2005. PMID: 15843827
-
Chronic myelogenous leukemia molecular signature.Oncogene. 2003 Jun 19;22(25):3952-63. doi: 10.1038/sj.onc.1206620. Oncogene. 2003. PMID: 12813469
-
The impact of gene profiling in chronic myeloid leukaemia.Best Pract Res Clin Haematol. 2009 Jun;22(2):181-90. doi: 10.1016/j.beha.2009.04.002. Best Pract Res Clin Haematol. 2009. PMID: 19698927 Review.
-
National Oncology Forum: perspectives for the year 2000.Cancer J. 2001 Jul-Aug;7 Suppl 1:S2-13. Cancer J. 2001. PMID: 11504281 Review.
Cited by
-
Development of a clinical microarray system for genetic analysis screening.Pract Lab Med. 2022 Dec 23;33:e00306. doi: 10.1016/j.plabm.2022.e00306. eCollection 2023 Jan. Pract Lab Med. 2022. PMID: 36593945 Free PMC article.
-
Confounding Factors in the Transcriptome Analysis of an In-Vivo Exposure Experiment.PLoS One. 2016 Jan 20;11(1):e0145252. doi: 10.1371/journal.pone.0145252. eCollection 2016. PLoS One. 2016. PMID: 26789003 Free PMC article.
-
Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples.BMC Med Genomics. 2012 Jan 30;5:6. doi: 10.1186/1755-8794-5-6. BMC Med Genomics. 2012. PMID: 22289410 Free PMC article.
-
Inferring tumour purity and stromal and immune cell admixture from expression data.Nat Commun. 2013;4:2612. doi: 10.1038/ncomms3612. Nat Commun. 2013. PMID: 24113773 Free PMC article.
-
Computational deconvolution: extracting cell type-specific information from heterogeneous samples.Curr Opin Immunol. 2013 Oct;25(5):571-8. doi: 10.1016/j.coi.2013.09.015. Epub 2013 Oct 19. Curr Opin Immunol. 2013. PMID: 24148234 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials